• Alzheimer's disease (AD) is the most prevalent dementia (accounting for 50%-75% of cases of dementia in people aged over 65 years), followed by frontotemporal dementia (FTD) (10%-20% of cases).
• AD is characterised histopathologically by Aβ-containing amyloid plaques and tau-containing neurofibrillary tangles, whereas FTD exhibits neurofibrillary tangles alone.
• Current symptomatic treatments of AD are of limited benefit, as they are not directed at the underlying biological basis of the disease.
• The development of transgenic animal models has provided insight into disease mechanisms and helped define novel drug targets.
• More than 50 drugs are currently in clinical trials, and novel and more effective drugs targeting both AD and FTD are expected to become available within 5-10 years.
|Number of pages||4|
|Journal||Medical Journal of Australia|
|Publication status||Published - 2 Oct 2006|